CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 362 enrolled
Drug / intervention
Aceclidine+Brimonidine combination ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05753189
NCT05753189Phase 3Completed
CompareCT.gov

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

LENZ Therapeutics, Inc·interventional·Posted Mar 3, 2023·Updated May 13, 2026

In Brief

A Phase 3 clinical trial evaluating Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, and 1 other intervention for Presbyopia and 3 related conditions. Completed, enrolled 362 participants across 40 sites.

Detailed Summary

Safety Study of the Long-Term Safety of LNZ100 \& LNZ101 in Presbyopic Subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia, Near Vision, Refractive Error, Eye Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMar 3, 2023
Enrollment StartFeb 21, 2023
Primary CompletionFeb 9, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.3 years ago

Interventions

Aceclidine+Brimonidine combination ophthalmic solutiondrug

Aceclidine + Brimonidine combination ophthalmic solution

Aceclidine ophthalmic solutiondrug

Aceclidine ophthalmic solution

Vehicledrug

Vehicle